查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球流感疫苗市場-2022-2029
市場調查報告書
商品編碼
1140687

全球流感疫苗市場-2022-2029

Global Flu Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

持續投資使定制流感疫苗生產規模擴大

隨著對通用流感疫苗的需求不斷增長，創新的科學和資金匯聚在一起，以幫助釋放尚未開發的商機。預計流感的迅速傳播將超過現有的流感疫苗製造技術，導致流感疫苗接種成本上升，對個人而言，情況相對不利。因此，創新通用流感疫苗需要持續的技術和資金投入。流感疫苗市場的市場參與者正專注於升級流感疫苗的製造工藝，以增加定制疫苗的產量。

流感疫苗是對抗多種病毒株的一種經濟有效的方法。預防所有流感的單一疫苗是另一個在流感疫苗市場獲得市場關注的開創性概念。此外，製造商正在增加對 mini-HA（血凝素）抗原的關注，其中包含在許多其他病毒中發現的部分流感病毒。通用流感疫苗將減輕每年更新流感疫苗的負擔，有助於降低研究人員和製藥公司的成本。

地理滲透。

北美將是預測期內的主要地區。

估計北美市場在全球流感疫苗市場佔據主導地位。這是由於該地區各國政府加大了努力，包括提高對流感、其影響和流感疫苗接種的認識的衛生計劃。此外，高度發達的醫療基礎設施和加拿大等國家的優惠報銷政策也是預計推動該地區國家市場增長的因素。該地區的多家主要公司已開始對通用流感疫苗進行新的試驗。例如，2022 年 6 月，一項針對通用流感疫苗的新試驗在 NIH 臨床中心開始了第一階段。本研究探討了 BPL-1357 的安全性，並證明了粘膜免疫對流感的重要性，以及誘導免疫系統的細胞和抗體臂對不斷變化的流感病毒提供更廣泛保護的策略。我們正在評估我們是否可以提供

在預測期內，由於對流感疫苗接種的認識不斷提高，以及該地區各國政府採取免費流感疫苗接種的舉措，預計亞太地區流感疫苗市場將在全球市場中佔據很大份額。 .此外，一些新興國家和發展中國家的流感病例上升預計將支持該地區的市場增長。

競爭格局。

由於主要食品品牌的存在，流感疫苗市場是一個競爭激烈的市場。對全球市場增長做出貢獻的重要流感疫苗製造商包括阿斯利康、葛蘭素史克、賽諾菲、雅培、Sequirus、田邊三菱製藥、印度血清研究所、Mylan NV、GDK Biotechnology、華蘭生物工程公司、Adimmune Corporation、Sinovac Biotech 、長春生物製品研究所等主要參與者正在根據流感疫苗市場的全球增長戰略採用新材料發布或新發布。一些主要的關鍵參與者正在遵循合併和合作戰略來擴展他們的業務。例如，2022 年 5 月，葛蘭素史克收購了臨床階段生物製藥公司 Affinivax, Inc.。此次收購提供了獲得第二階段開發中的下一代 24 價肺炎球菌候選疫苗和高度創新的 MAPSTM 技術的途徑。此次收購還支持強大的創新疫苗和特種藥物組合。 2022年7月，葛蘭素史克與加拿大政府簽署了流感疫苗協議。根據該協議，該公司將供應約 8000 萬劑 Arepanrix 和 1600 萬劑 Flulaval Tetra。該公司有意從其位於魁北克的 230,000 平方英尺的 Sainte-Foy 工廠採購這兩種疫苗。 2020 年 2 月，雅培推出了一種用於廣泛預防流感的新疫苗。該疫苗針對兒童和成人的四種流感病毒株針對上一代的三種病毒株提供廣譜保護。該疫苗僅批准用於 3 歲以下兒童。對4種流感病毒株有效。

COVID-19 的影響將對全球流感疫苗市場產生積極影響。

由於 COVID-19 疫苗在大流行的早期階段尚未上市，因此人們越來越有興趣評估流感疫苗在 COVID-19 易感性和嚴重性中的作用。與未接種流感疫苗的人相比，接種流感疫苗的人 COVID-19 檢測呈陽性的可能性降低了 24%。結論：接種流感疫苗的患者不太可能需要住院或機械通氣並且住院時間較短。流感疫苗可減輕 COVID-19 的負擔。一些製造商在大流行期間增加了銷量。例如，2020 年 10 月，賽諾菲第三季度受到創紀錄的流感疫苗銷售增長和 Dupixent 成功的推動。僅流感疫苗銷售額就增長了 44.9%，達到創紀錄的 10.7 億歐元，成功部分抵消了 COVID-19 爆發對腦膜炎疫苗 Menactra 及其成人加強疫苗和旅行疫苗的影響。

本報告提供了大約 61 個市場數據表、57 個圖表和 170 頁有關全球流感疫苗市場的信息。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按類型劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按應用劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 繼續投資擴大定制流感疫苗的生產規模
      • 對通用流感疫苗的需求增加
    • 限制因素
      • 產品的高成本和疫苗的劑量限制了其吸收
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST 分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 全病毒疫苗
  • 分裂病毒疫苗
  • 亞單位疫苗
  • 減毒活疫苗

第 8 章分銷渠道

  • 機構投資者
  • 醫院
  • 區域診所
  • 公共衛生機構
  • 工作場所
  • 零售
  • 零售藥房
  • 郵購藥房

第 9 章按應用程序

  • 適用於 3 歲以下兒童
  • 適用於 3 歲以上的兒童和成人

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • 阿斯利康
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • GlaxoSmithKline PLC
  • Sanofi
  • Abbott Laboratories
  • Seqirus
  • Mitsubishi Tanabe Pharma
  • Serum Institute of India Pvt. Ltd
  • Mylan NV
  • GDK Biotechnology
  • Hualan Biological Engineering Inc.
  • Adimmune Corporation
  • Sinovac Biotech
  • Changchun Institute of Biological Products（List Not Exhaustive）

第13章 重要考察

第14章 DataM

簡介目錄
Product Code: DMHCIT3078

Market Overview

Flu Vaccine Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.8% during the forecast period (2022-2029).

The flu vaccine is inactivated, indicating that it includes the killed influenza virus, or a recombinant vaccine, implying that it was made without exploiting virus particles. Flue vaccination is safe and effective. Healthcare providers infuse the vaccine into muscles or skin, encouraging the immune system to produce antibodies to the influenza virus. Medical professionals administer the "flu shot" vaccine as a single dose of liquid injected through the skin into the muscle. The health care professionals inject the flu vaccine into the deltoid muscle at the side of the arm, using alcohol rubbed over the skin for sterilization. Market players in the flu vaccines are increasing their R&D activities to develop innovative vaccines that can treat COVID-19. They are helping persons to refrain from visiting doctors amidst ongoing pandemics. Increased flu vaccine availability is expected to reduce the stress on healthcare systems and minimize exposure to COVID-19.

Market Dynamics: Sustained investments help to scale-up production of tailor-made flu vaccines

The demand for universal flu vaccines increases innovative science and financing to join forces to support exploit of untapped opportunities. The rapid arrival of influenza is expected to overtake the prevailing flu vaccine production technologies, resulting in increased costs of flu shots, which is comparatively ominous for individuals. Thus, there is a need for continuous investments in both technical and financial to innovate universal flu vaccines. The flu vaccines market's market players are focusing on upgrading the flu vaccine manufacturing processes to raise the production of tailor-made vaccines.

Flu vaccine is a Cost-efficient way to combat multiple viral strains. The single vaccine that safeguards against all flu is another groundbreaking concept gaining market players' traction in the flu vaccines market. Moreover, the manufacturers are increasing their focus on mini-HA (Hemagglutinin) antigens that include parts of the flu virus found in numerous other viruses. Universal flu vaccines assist in reducing the burden of yearly updates in flu shots, therefore, saving on costs for researchers and pharma companies.

Market Segmentation: The whole virus segment accounted for the highest share in global flu vaccine market.

The flu vaccine market has been classified into whole virus vaccines, split virus vaccines, subunit vaccines, and live attenuated virus vaccines based on the vaccine.

The whole virus vaccines segment held a dominant position with a major share in terms of value in the global market and is projected to remain at its position over the forecast period. Whereas the live attenuated virus vaccines segment is projected to record a considerable growth rate in the global market during the forecast period, owing to the increasing adoption of advanced vaccines for prevention purposes.

The flu vaccine market has been classified into anti-intrusion bars, heat exchangers, sound insulation, and others based on the application.

Adults and Children over 3 year's segment dominated the global flu vaccine market in the forecast period. The adults and children aged 3 years and above segment are estimated to contribute the maximum share in terms of value in the target market due to increasing incidences of flu viruses among adults and children over 3 years of age globally.

Geographical Penetration: North America is the dominating region during the forecast period.

The North America market is estimated to hold the dominant position in the global flu vaccines market. This is due to the governments increasing initiatives, such as health programs for expanding awareness concerning influenza, its possible effects, and flu vaccination in countries in the region. Highly developed healthcare infrastructure and the existence of favorable reimbursement policies in countries such as Canada are additional factors projected to boost market growth in countries in the region. Various key players in the region started new trials for the universal flu vaccine. For instance, in June 2022, a new trial for the universal flu vaccine started at NIH Clinical Center in phase 1. This study examines the safety of BPL-1357 and assesses the importance of mucosal immunity against flu and whether a strategy of inducing both the cellular and antibody arms of the immune system can provide broader protection against the ever-changing influenza virus

The Asia Pacific flu vaccine market is projected to gain a significant share in the global market over the forecast period due to increasing awareness regarding flu vaccination and government initiatives for free flu vaccinations in countries in the region. Moreover, the increasing patient pool for flu in several developing and poorly developed countries is expected to support the growth of the market in the region.

Competitive Landscape:

The flu vaccine market is highly competitive, owing to the presence of big food brands. The critical flu vaccine players which are contributing to the growth of the global market include AstraZeneca, GlaxoSmithKline PLC, Sanofi, Abbott Laboratories, Seqirus, Mitsubishi Tanabe Pharma, Serum Institute of India Pvt. Ltd, Mylan NV, GDK Biotechnology, Hualan Biological Engineering Inc., Adimmune Corporation, Sinovac Biotech, and Changchun Institute of Biological Products, among others. The major players are adopting new launches based on new material launches and expansion strategies for global growth in the flu vaccine market. Some major key players follow merger and collaboration strategies to expand their business. For instance, in May 2022, GSK acquired clinical-stage biopharmaceutical company Affinivax, Inc. This acquisition provides access to next-generation 24-valent pneumococcal vaccine candidates in phase II development and highly innovative MAPSTM technology. This acquisition also supports a strong portfolio of innovative vaccines and specialty medicines. In July 2022, GSK entered into an agreement with the Government of Canada for the influenza vaccine. The company supplies nearly 80 million doses of Arepanrix and 16 million doses of Flulaval Tetra under the deal. The company intends both vaccines from its 230,000ft² Sainte-Foy facilities in Quebec. In February 2020, Abbot launched a new vaccine for wide protection against influenza. This vaccine offered wide coverage protection against four flu virus strains for children and adults versus three strains in the previous generation. This vaccine is approved for only children below the age of 3 years. It is effective against four different flu virus strains.

COVID-19 Impact: Positive impact on the global flu vaccine market.

COVID-19 vaccine is not available in the market at the initial stage of the pandemic, so there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. The possibility of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not by 24%. Patients vaccinated with the flu vaccine were less likely to require hospitalization or mechanical ventilation and had a shorter hospital length of stay. The flu vaccine reduces the burden of COVID-19. Some manufacturers increase their sales during the pandemic. For instance, in October 2020, Sanofi's Q3 was boosted by record growth in flu vaccine sales and Dupixent success. Sales for influenza vaccines alone grew by a record 44.9% to €1.07 billion during the quarter, which managed to partially offset the impact of the COVID-19 outbreak on the meningitis vaccine Menactra and its adult booster and travel vaccines.

The global flu vaccine market report would provide an access to approximately 61 market data tables, 57 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Sustained investments help to scale up production of tailor-made flu vaccines
      • 4.1.1.2. Increasing demand for universal flu vaccines
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of the product coupled with the dosage of the vaccine to limit adoption
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Whole virus vaccines*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Split vurus vaccines
    • 7.3.3. Subunit vaccines
    • 7.3.4. Live attenuated virus vaccines

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Institutional*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Hospitals
    • 8.3.3. Community clinics
    • 8.3.4. Public health agencies
    • 8.3.5. Workplaces
    • 8.3.6. Retails
    • 8.3.7. Retail pharmacy
    • 8.3.8. Mail order pharmacy

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. For Children below 3 years*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. For Adults and Children over 3 years

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AstraZeneca*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline PLC
  • 12.3. Sanofi
  • 12.4. Abbott Laboratories
  • 12.5. Seqirus
  • 12.6. Mitsubishi Tanabe Pharma
  • 12.7. Serum Institute of India Pvt. Ltd
  • 12.8. Mylan NV
  • 12.9. GDK Biotechnology
  • 12.10. Hualan Biological Engineering Inc.
  • 12.11. Adimmune Corporation
  • 12.12. Sinovac Biotech
  • 12.13. Changchun Institute of Biological Products (List Not Exhaustive)

13. Premium Insights

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us